Morgan Stanley’s TriVascular Technologies TRIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
– Sell
-4,560
Closed -$30K – 6958
2015
Q4
$30K Sell
4,560
-15,064
-77% -$100K ﹤0.01% 5909
2015
Q3
$99K Sell
19,624
-4,460
-19% -$24K ﹤0.01% 5428
2015
Q2
$129K Buy
24,084
+1,273
+6% +$9.03K ﹤0.01% 5457
2015
Q1
$239K Buy
22,811
+21,334
+1,444% +$220K ﹤0.01% 5118
2014
Q4
$19K Buy
1,477
+594
+67% +$8.1K ﹤0.01% 6072
2014
Q3
$13K Sell
883
-29,081
-97% -$422K ﹤0.01% 6132
2014
Q2
$466K Buy
+29,964
New +$455K ﹤0.01% 4630

Morgan Stanley's TRIV Position: Q1 2016 in Review

Morgan Stanley sold out of TriVascular Technologies (TRIV) in Q1 2016, closing a stake of 4,560 shares — an estimated $30K sold.

Morgan Stanley first reported a position in TRIV in Q2 2014 and held it in 7 quarters. The position peaked at $466K in Q2 2014. 0 funds tracked by Wall St. Rank hold TRIV as of Q1 2016.

  • Morgan Stanley reported no remaining TriVascular Technologies position as of Q1 2016 after selling out during the quarter.
  • Morgan Stanley sold 4,560 TriVascular Technologies shares in Q1 2016, an estimated $30K.
  • Morgan Stanley first reported a position in TriVascular Technologies in Q2 2014 and held it in 7 quarters.
  • Morgan Stanley's TriVascular Technologies position peaked at $466K in Q2 2014.
  • 0 funds tracked by Wall St. Rank held TriVascular Technologies as of Q1 2016.

Based on Morgan Stanley's 13F filing for Q1 2016, filed 12 May 2016.